Halberd's PTSD/Alzheimer's R&D Reveals Link to Potential Obesity Cure
JACKSON CENTER, PA / ACCESSWIRE / October 20, 2021 / Halberd Corporation's (OTC PINK:HALB) ongoing research into discovering treatments/cures for PTSD, Alzheimer's Disease, and other neurodegenerative diseases has led to a potential breakthrough in the battle against obesity. Research has indicated inflammatory cytokines present in the Cerebral Spinal Fluid (CSF) of neurodegenerative disease patients are also found in the blood of those suffering from obesity.
Halberd's patent-pending extracorporeal treatment for removing the disease antigens, excess proteins and cytokines from CSF associated with neurodegenerative diseases can similarly be applied to eliminating the chemical imbalances in blood believed to be responsible for obesity. Removal of these elements from blood would therefore reduce or eliminate the negative health issues associated with obesity, such as high blood pressure, diabetes, heart disease, stroke, cancer, etc. It has been known for several years that obesity is linked to higher risks of death.
Further research is underway with Halberd's university partners.
William A. Hartman, Chairman, President and CEO of Halberd Corporation, stated, "Our plans to pursue cures for PTSD and Alzheimer's Disease involve the removal of select inflammatory cytokines from CSF and blood plasma. We are rapidly pursuing elimination of these target pathogens from CSF and intend to address removal from blood plasma as soon as possible. What is exciting about this development concerning obesity is that our scientists didn't have to initiate any new experimentations, but rather relied on numerous medical articles to affirm our direction."
To get the latest news on Halberd's exciting medical developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies: Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287 and an allowed but not yet issued patent for the treatment of Cockayne Syndrome
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
SOURCE: Halberd Corporation
View source version on accesswire.com: